Novo Nordisk Q1 2026: Wegovy Pill Sales Decline but Expectations Raised

Novo Nordisk announced its financial results for the first quarter of 2026. Despite a decline in sales of the Wegovy pill, the company performed above general expectations. This boosted investor confidence in the company's future growth potential. According to the company's statement, the decline in Wegovy pill sales was primarily due to competitive pressures in certain markets. However, strong performance in Novo Nordisk's other product groups offset this decline. The company managed to increase revenues, particularly through its innovative product portfolio in diabetes and obesity treatments. The financial results showed that the company's net profit and revenues exceeded analyst expectations. Novo Nordisk attributed this success to operational efficiency and cost control measures. Additionally, the company continues its strategy of focusing on new treatment areas by increasing R&D investments. Novo Nordisk management revised its growth expectations upward for 2026. Following the temporary decline in Wegovy pill sales, the company expects a recovery through new product launches and market expansion. This optimistic outlook had a positive impact on stock prices. This is not investment advice.